Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$42.41M-97.0%-$27.85M-48.3%-$32.73M-28.2%-$26.88M-28.4%-$21.53M+10.5%
$295K+4.2%$299K-1.6%$200K-33.3%$300K0.0%$283K-12.9%
$5.55M+68.4%$3.53M+9.7%$3.29M-2.1%$3.19M-4.3%$3.29M+3.0%
-$40.88M-85.6%-$26.72M-46.0%-$24.17M-11.8%-$20.18M+6.1%-$22.02M-11.2%
$24K-93.7%$250K$108K+209%$2K-99.0%$378K+170%
-$3.02M-715%-$247K-$48K-37.1%-$371K-165%
$711K+1,467%$49.56M$8.8M+33.4%$216.29M+207%-$52K-136%
-$43.19M-92.4%$22.59M+221%$0+100%$196.17M+302%-$22.44M-12.4%
-$40.9M-82.6%-$26.97M-47.3%-$24.27M-12.1%-$20.18M+7.0%-$22.4M-12.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Taysha Gene Therapies, Inc. generate?
Taysha Gene Therapies, Inc. (TSHA) generated -$111.9M in operating cash flow over the trailing twelve months.
What is Taysha Gene Therapies, Inc.'s free cash flow?
After $384.0K of capital expenditures, Taysha Gene Therapies, Inc.'s free cash flow was -$112.3M over the trailing twelve months, down 33.6% year over year.
Where does Taysha Gene Therapies, Inc.'s cash flow data come from?
Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.